iOnctura

#BioIVT #Cancer research #Drug development #Drug discovery #iOnctura #Kazia Therapeutics #Sartorius #Vyriad Therapeutics #Webinar

Last chance to register: Drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics… Read More

#News

#BioIVT #Cancer research #Drug development #Drug discovery #iOnctura #Kazia Therapeutics #Sartorius #Vyriad Therapeutics #Webinar

Webinar explores drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics… Read More

#News

Cancer cells
#BioIVT #Cancer research #Drug development #Drug discovery #iOnctura #Kazia Therapeutics #Sartorius #Vyriad Therapeutics #Webinar

Drug discovery challenges in cancer research webinar

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at… Read More

#News

#BioIVT #Cancer research #Drug development #Drug discovery #iOnctura #Kazia Therapeutics #Sartorius #Vyriad Therapeutics #Webinar

Register to learn about the drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics… Read More

#News

Cancer cells
#BioIVT #Cancer research #Drug development #Drug discovery #iOnctura #Kazia Therapeutics #Sartorius #Vyriad Therapeutics #Webinar

New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics… Read More

#News

Cancer cells
#BioIVT #Cancer research #Drug development #Drug discovery #iOnctura #Kazia Therapeutics #Sartorius #Vyriad Therapeutics #Webinar

Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics… Read More

Webinar date:
Co-sponsored by BioIVT and Sartorius
#Webinars

Scientist in laboratory
#AI #Clinical trial #iOnctura #Poolbeg Pharma #Regulatory #Synklino #Weatherden

Expert opinion: Navigating the challenges in the clinical trials sector

On International Clinical Trials Day, industry experts speak to DDW about the current state of play within global clinical trials. DDW: How encouraged are you by regulatory reforms – whether it’s a focus on the use of NAMs, or faster regulatory review processes – to help companies conduct more efficient and effective trials? Liam Tremble: A lot… Read More

#Exclusive Content #Regulatory

Pancreatic cancer
#iOnctura #Oncology #Pancreatic cancer #Phase I trial

mPDAC treatment reaches primary endpoint in Phase Ib trial

Cambritaxestat, a treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC), has met its primary endpoint in a Phase Ib trial. Cambritaxestat, an oral autotaxin (ATX) inhibitor, was evaluated in patients with previously untreated mPDAC. The treatment demonstrated safety, tolerability and anti-tumour responses, with data presented at the European Society… Read More

#Cancer Research #News

Eye
#Cancer research #Eye health #iOnctura

Phase II study in metastatic uveal melanoma commences

iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, has dosed the first patient in the randomised Phase II OCULE-01 study investigating lead asset roginolisib in patients with metastatic uveal melanoma (UM), a rare cancer of the eye. Roginolisib is an orally dosed small molecule allosteric modulator of PI3Kδ. Read More

#Cancer Research #News

Rare Disease Day
#Biomedical research #Connecta #iOnctura #Rare disease #Rare Disease Day #SpliceBio

Rare Disease Day 2025: Q&A with industry experts

Rare Disease Day is an observance held on the last day of February annually to raise awareness for rare diseases and improve access to treatment and medical representation for individuals with rare diseases and their families. To mark Rare Disease Day 2025, DDW gathered insight from a range of industry… Read More

#Business & Investment #Exclusive Content #Opinion

Pancreatic cancer
#Cancer research #iOnctura #Pancreatic cancer #Tumours

Breaking barriers in pancreatic cancer

World Pancreatic Cancer Day takes place on 21 November to raise awareness about pancreatic cancer, support patients and their families, and advocate for increased research and early detection of this deadly disease. iOnctura’s Chief Medical Officer Michael Lahn discusses how we can fight the disease by breaking the defensive wall surrounding… Read More

#Cancer Research #Exclusive Content

Non-small cell lung cancer
#Checkpoint inhibitor therapies #iOnctura #Lung cancer #Non-small cell lung cancer (NSCLC) #Phase II trial

Cancer ‘master switch’ study expands to lung cancer

iOnctura has expanded its clinical trial programme for roginolisib to include non-small cell lung cancer (NSCLC). Via clinical collaboration agreements with the ETOP IBCSG Partners Foundation and GSK, roginolisib will be evaluated in a Phase II study in combination with dostarlimab in patients with NSCLC… Read More

#Cancer Research #News

#Cancer research #Clinical trials #Funding #iOnctura #Non-small cell lung cancer (NSCLC) #Seed funding

iOnctura announces €80m to progress pipeline  

iOnctura has closed an €80 million Series B financing to continue developing a portfolio of precision oral small molecules that target cancers in novel ways.   The funding round was led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council… Read More

#Business & Investment #Cancer Research #News

Pancreatic cancer
#FDA #Fibrosis #iOnctura #Oncology #Orphan drugs #Pancreatic cancer

Orphan Drug Designation for first-in-class autotaxin cancer therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to iOnctura for its autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer. After assessing its novel chemical and biological properties, including an attractive non-clinical safety and efficacy profile, the FDA has granted Orphan Drug Status, conferring… Read More

#Cancer Research #News #Regulatory

Cancer tumour
#Biotechnology #Cancer research #iOnctura #Tumours

New research highlights potential of combination cancer treatment 

iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways, has published new research data in the peer-reviewed journal Cancer Research, that supports a strategy of combining autotaxin inhibitor IOA-289 with TGF-β pathway inhibitor IOA-359.   Resistance to TGF‐β… Read More

#Cancer Research #News

Cancer cell
#Biotech #Cancer #iOnctura #Oncology #Pharmaceuticals

iOnctura expands pipeline and receives development grant 

iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways, has exercised an exclusive option with Clavius Pharmaceuticals, adding the novel oral TGF-β pathway inhibitor, IOA-359, to its pipeline.   IOnctura also announced it has, in collaboration with the… Read More

#News